Profil Hematologi Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP Prof. Dr. R.D. Kandou Manado Periode Januari-Desember 2023
DOI:
https://doi.org/10.35790/ecl.v13i3.62329Abstract
Abstract: One of the side effects found in cancer patients undergoing chemotherapy is bone marrow suppression. Hematology profile is crucial both to determine the side effects related to chemotherapy performed and as a parameter to start the next cycle of therapy. This study aimed to determine the hematological profile of breast cancer patients undergoing chemotherapy at Prof. Dr. R. D. Kandou Hospital, Manado, from January to December 2023. This was a retrospective and descriptive study with a cross-sectional design, using medical record data. The results obtained 61 cases, dominated by the age group 45-60 years (65.6%), stage 3b (49.2%), and CAF as the most used chemotherapy regimen (23%). The hematology profile of breast cancer patients undergoing chemotherapy was as follows: average Hb 10.7 g/dL, leukocytes 7.8 103/uL, platelets 289.2 103/uL, hematocrit 31.3%, rod neutrophils 1.01%, segment neutrophils 56.4%, basophils 0.05%, eosinophils 1.52%, basophils 29.7%, monocytes 10.6%, MCV 83.7 fL, MCH 28.8 pg, and MCHC 34.1 g/dL. In conclusion, the average hematology values of Hb, stem neutrophils, basophils, hematocrit were below normal. The average value of monocytes was above normal. While the average values of leukocytes, segment neutrophils, lymphocytes, eosinophils, platelets, MCV, MCH and MCHC are within the normal range.
Keywords: hematology profile; breast cancer; chemotherapy
Abstrak: Salah satu efek samping yang ditemukan pada pasien kanker yang menjalani kemoterapi ialah supresi pada sumsum tulang. Profil hematologi merupakan hal yang krusial baik untuk mengetahui efek samping terkait kemoterapi maupun sebagai parameter untuk memulai siklus terapi selanjutnya. Penelitian ini bertujuan untuk mengetahui profil hematologi pasien kanker payudara yang menjalani kemoterapi di RSUP Prof. Dr. R. D. Kandou, Manado, periode Januari– Desember 2023. Jenis penelitian ialah deskriptif retrospektif dengan desain potong lintang, menggunakan data rekam medik. Hasil penelitian mendapatkan 61 kasus, didominasi oleh kelompok usia 45-60 tahun (65,6%), dengan stadium terbanyak ialah 3b (49,2%) serta regimen kemoterapi yang sering digunakan ialah CAF (23%). Profil hematologi pasien kanker payudara yang menjalani kemoterapi ialah sebagai berikut: rerata Hb 10,7 g/dL, leukosit 7,8 103/uL, trombosit 289,2 103/uL, hematokrit 31,3%, neutrofil batang 1,01%, neutrofil segmen 56,4%, basofil 0,05%, eosinofil 1,52%, basofil 29,7%, monosit 10,6%, MCV 83,7 fL, MCH 28,8 pg, serta MCHC 34,1 g/dL. Simpulan penelitian ini ialah rerata nilai profil hematologi dari Hb, neutrofil batang, basofil, hematokrit mengalami penurunan dari nilai normal. Nilai rerata monosit mengalami peningkatan dari nilai normal. Rerata nilai dari leukosit, neutrofil segmen, limfosit, eosinofil, trombosit, MCV, MCH dan MCHC berada dalam rentang hasil yang normal.
Kata kunci: profil hematologi; kanker payudara; kemoterapi
References
Ferri FF. Ferri’s Clinical Advisor 2020: 5 books in 1. Philadelphia, Pa: Elsevier; 2020.
World Health Organization. Global Breast Cancer Initiative Implementation Framework Assessing, Strengthening and Scaling-Up of Services for the Early Detection and Management of Breast Cancer. Executive Summary. Geneva: WHO; 2023. Available from: https://www.who.int/publications-detail-redirect/9789240067134
Kementerian Kesehatan Republik Indonesia. Laporan Riskesdas 2018 Nasional. Jakarta: Kementerian Kesehatan RI; 2018. Available from: Laporan Nasional Riskesdas 2018 - Repositori Badan Kebijakan Pembangunan Kesehatan
Sudoyo AW, Setiyohadi B, I Alwi, M Simadibrata, S Setiati. Buku Ajar Ilmu Penyakit Dalam (5th ed). Jakarta: Interna Publishing; 2009.
Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy. Cur Cancer Ther Rev. 2006;2(3):271–9. Doi:10.2174/157339406777934717
Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu X-O, et al. Chemotherapy-induced toxicities and their associations with clinical and non-clinical factors among breast cancer patients in Vietnam. Cur Oncol Rep. 2022;29(11):8269–84. Doi:10.3390/curroncol29110653
Wondimneh B, Setty SAD, Asfeha GG, Belay E, Gebremeskel G, Baye G. Comparison of hematological and biochemical profile changes in pre-and post-chemotherapy treatment of cancer patients attended at Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia. Cancer Manag Res. 2021;13:625–32. Doi: 10.2147/CMAR.S274821
Duong CD, Loh JY. Laboratory monitoring in oncology. J Oncol Pharm Pract. 2006;12(4):223–36. Doi: 10.1177/1078155206072982
Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e207. Doi: 10.1016/S1470-2045(19)30145-7
Chambers P, Wei L, Forster MD, Kipps E, Wong ICK, Jani Y. Evidence to guide the optimal timing for pre-chemotherapy blood tests fo r early breast, colorectal cancer and diffuse large B-cell lymphoma. Cancer Med. 2021;10(22):7996–8004. Doi: 10.1002/cam4.4316
Gatsu PD, Cahyani AA, Candra DID, Novitasari N. Hubungan faktor risiko usia dengan angka kejadian kanker payudara dan tumor jinak payudara di RSUD Wangaya Kota Denpasar tahun 2019-2022. Borneo J Med Lab Tech. 2023;6(1):434–41. Doi:10.33084/bjmlt.v6i1.6085
Shoemaker ML, White MC, Wu M, Weir HK, Romieu I. Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013. Breast Cancer Res Treat. 2018;169(3):595–606. Doi:10.1007/s10549-018-4699-9
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer. Version 4.2023. NCCN website. Available from: https://www.nccn.org
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51. Doi: 10.1016/S1470-2045(12)70425-4
Huljannah M, Irawiraman H, Hasanah N. Frekuensi dan karakteristik kanker payudara pada wanita usia muda di RSUD Abdul Wahab Sjahranie Samarinda tahun 2018–2020. J Ked Mulawarman. 2023;10(1):21–7. Doi: https://doi.org/10.1234/jkm.v10i1.5678
Fuentes JDB, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, et al. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol. 2024;10(1):71–8. Doi: 10.1001/jamaoncol.2023.4837
Arisanti JP, Saptarina N, Andarini YD. Evaluasi penggunaan obat kemoterapi pada penderita kanker payudara di RSUP Dr. Seoradji Tirtonegoro periode 2018. Pharmasipha. 2020;4(2):98–105. Doi: 10.1234/pharmasipha.v4i2.4960
Pedoman Nasional Pelayanan Kedokteran (PNPK): Tata Laksana Kanker Payudara [Internet]. Kementerian Kesehatan RI. Available from: https://www.kemkes.go.id/id/pnpk-2018---tata-laksana-kanker-payudara
Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran (11th ed). Jakarta: Penerbit Buku Kedokteran EGC; 2006.
Storph RP, Ghartey FN, Ephraim RK, Mensah E, Mornah M, Ahenkorah-Fondjo L, et al. The effect of chemotherapy on clinical, hematological and biochemical profile in breast cancer patients undergoing chemotherapy at Cape Coast Teaching Hospital: A longitudinal study. J Cancer Tumor Int. 2019;9(4)1–9. Doi: 10.9734/jcti/2019/v9i230104
Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero_Martin M, Gómez-Salgado J, et al. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore). 2020;99(33):e21695. Doi: 10.1097/MD.0000000000021695
Gilmore N, Mohile S, Lei L, Culakova E, Mohamed M, Magnuson A, et al. The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Res. 2021;23(1):19. Doi: 10.1186/s13058-021-01388-w
Nabilah A, Prabowo WC, Hadi Kuncoro H. Pengaruh kemoterapi terhadap kadar hematologi pada pasien kanker payudara di RSUD Dr. Kanujoso Djatiwibowo Balikpapan. J Mandala Pharmacon Indones. 2024;10(1):45–53. Doi: 10.35311/jmpi.v10i1.474
Raharjo DD. Prevalensi trombositopenia pada pasien kanker payudara setelah kemoterapi di RSUD Dr. Mohammad Soewandhie Surabaya periode Januari–Desember 2018. J Univ Airlangga. 2019;12(4): 78–84. Doi: 10.1234/jua.v12i4.5678
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nabila H. Khatimah, Linda W. A. Rotty, Octavianus R. H. Umboh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
